PCI Biotech

PCI Biotech leveraged its photochemical technology platform, originating from research at Oslo University Hospital, to address key challenges in drug delivery and biomanufacturing. The company focused on two main applications: PCI for enhancing the intracellular delivery of therapeutics in oncology and dermatology, and PCL for improving yield and purity in viral vector manufacturing for gene therapies. Despite reaching preclinical and early clinical stages with its technologies, the company's shareholders resolved to dissolve and delist the company in 2026, ceasing its development activities.

A photochemical platform using a proprietary photosensitizer and light to trigger either endosomal release for enhanced intracellular drug delivery (PCI) or selective cell lysis for improved viral vector manufacturing (PCL).

In drug delivery, PCI competed with lipid nanoparticles, viral vectors, and other physical delivery methods. In bioprocessing, PCL competed with standard chemical and mechanical cell lysis techniques. Its key differentiation was the precise, light-triggered control over membrane disruption, aiming for improved specificity and reduced impurities compared to conventional methods.